# Market Mayhem: Reverse Splits and Cannabinoid Clouts! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-08-31T14:01:00.301Z Source: https://newsyai.com/edition/4ac1a1ec-8e49-42f7-acd6-35acc1d8d510 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Market Mayhem: Reverse-Split Circus 13.0 – Cannabinoid Clouts, Crude Cowboys & Cancer Resistance Rebels (August 31, 2026 Edition!)** Futures mixed (Dow flatter than a day-trader’s excuses, Nasdaq still humping AI/chip hype like a desperate intern, crude oil doing its usual volatility pole dance). MVLS $5M drama on ice, but the microcap reverse-split conga line marches on toward delisting hell. Yesterday’s calcium clots, brain zaps, and edge lords? Ancient history. Fresh meat today: a lipid-signaling biopharma with a 1-for-9 (trading split-adjusted today), an oil-patch cowboy with a proactive 1-for-9 (same timeline), and a cancer-drug-resistance fighter with a 1-for-7 (effective tomorrow). Bulls howl “tiny float + pipeline tailwinds = moon”; bears smell cash burns, serial compliance theater, and dilution gangbangs.[[1]](https://capedge.com/stock-split-calendar) ### 1) ARTL (Artelo Biosciences, Inc.): “1-for-9 Cannabinoid Stiffy vs. Lipid-Signaling Cancer/Pain Pipeline & Tiny-Float Moonshot” **Why it’s loud** 1-for-9 reverse split; split-adjusted Nasdaq trading starts today (Aug 31). Clinical-stage player modulating lipid-signaling pathways for cancer, pain, dermatological, and neurological conditions. Recent U.S. and Japan patent allowances on lead candidate ART27.13 (peripherally selective dual cannabinoid agonist), Phase 2 trials in glaucoma and paclitaxel-induced peripheral neuropathy, plus nonclinical wins in osteoarthritis and spinal cord injury pain. Post-split float shrinks to ~547k shares.[[2]](https://www.globenewswire.com/news-release/2026/08/27/3351943/0/en/artelo-biosciences-announces-reverse-stock-split.html?pdf=1) **Bull case (compliance rocket + cannabinoid boner)** Modest 9x ratio + “patent-protected lipid tailwinds in hot oncology/pain markets” = $4–12+ rip on the microscopic float. Ride the biotech wave, degens—shrunken float + FDA momentum = explosive moves on any trial readout or partnership! **Bear case (dilution gangbang & pipeline limp dick)** Another compliance-driven split on a cash-burning clinical player with financing history screams desperation; ongoing raises and trial risks = sub-penny graveyard after the pop. Short the fade before the next treasury dump! **My take, first principles (real pipeline signal vs. listing cancer)** Genuine cannabinoid science, fresh patents, and multiple Phase 2 assets could fuel short-term momentum on data/news, but repeated compliance fights, clinical-stage cash burn, and microcap volatility scream high-risk lottery ticket. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.12–3.20** range, **$0.55C** lipid pump—**P$0.12** dilution fade. ### 2) TPET (Trio Petroleum Corp.): “1-for-9 Crude Cowboy Stiffy vs. Oil/Gas Acquisitions & NYSE American Listing Panic” **Why it’s loud** 1-for-9 reverse split effective after close Aug 28; split-adjusted trading starts today (Aug 31). Proactive move to protect NYSE American listing amid acquisition/drilling growth strategy. Recent updates on North American oil/gas asset buys, ~$22M cash plus ATM raises, focus on near-term cash-flow producers.[[3]](https://www.benzinga.com/pressreleases/26/08/g61287077/trio-petroleum-corp-announces-proactive-reverse-stock-split-and-provides-shareholder-update-acquisit) **Bull case (compliance rocket + energy boner)** 9x ratio + “oil boom tailwinds + acquisition pipeline” = $2–7+ rip on the tightened float. Ride the crude wave, apes—shrunken float = massive percentage moves on any deal close or production update! **Bear case (dilution tsunami & execution limp dick)** Proactive split on a player with listing pressure and cash-burn history screams desperation; volatile energy markets and integration risks = sub-penny trap after the pop. Short the fade before the next offering! **My take, first principles (real asset signal vs. listing cancer)** Acquisition strategy and cash position could spark short-term volatility on deal/news, but compliance history, execution risks in a choppy oil market, and microcap dilution scream avoid beyond a quick scalp. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.09–2.10** range, **$0.40C** crude pump—**P$0.09** dilution fade. ### 3) KAPA (Kairos Pharma, Ltd.): “1-for-7 Cancer-Resistance Stiffy vs. Oncology Pipeline & NYSE American Bid-Price Squeeze” **Why it’s loud** 1-for-7 reverse split effective Sep 1 (split-adjusted trading tomorrow). Clinical-stage biopharma targeting cancer drug resistance. Recent pipeline updates on assets like ENV-105 and new acquisition term sheets; shareholder-approved split authority in a broad range.[[4]](https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/ex99-1.htm) **Bull case (compliance rocket + oncology boner)** 7x ratio + “drug-resistance tailwinds in hot cancer markets” = $1.50–5+ rip on the shrunken float. Ride the biotech wave, degens—tiny float + clinical momentum = explosive moves on any trial win or partnership! **Bear case (dilution gangbang & pipeline limp dick)** Compliance-driven split on a cash-burning clinical player screams desperation; ongoing raises and trial risks = sub-penny graveyard after the pop. Short the fade before the next treasury dump! **My take, first principles (real pipeline signal vs. listing cancer)** Oncology resistance focus and pipeline expansion could fuel short-term momentum on data/news, but listing deficiencies, dilution history, and microcap volatility scream high-risk lottery ticket. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.08–1.80** range, **$0.35C** resistance pump—**P$0.08** dilution fade. **Tape-Side Tactics (ARTL Cannabinoid Clouts, TPET Crude Cowboys & KAPA Cancer Rebels – August 31 Edition)** - **ARTL**: **$0.12–3.20** stiffy; **$0.55C** lipid pump, **P$0.12** fade. - **TPET**: **$0.09–2.10** stiffy; **$0.40C** crude pump, **P$0.09** fade. - **KAPA**: **$0.08–1.80** stiffy; **$0.35C** resistance pump, **P$0.08** fade. MVLS pressure paused but reverse-split addiction still tightening the noose amid AI hype and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions! **Sources** (for tracking every claim above): - Reverse splits & reactions: GlobeNewswire, SEC filings, StockTitan, TipRanks, Yahoo Finance, Benzinga (ARTL, TPET, KAPA announcements, Aug 18–27 2026 data).[[2]](https://www.globenewswire.com/news-release/2026/08/27/3351943/0/en/artelo-biosciences-announces-reverse-stock-split.html?pdf=1) - Company details & announcements: Company press releases, Nasdaq/ NYSE notices, and 8-K filings via the above. - Broader microcap/premarket context & volatility: Yahoo Finance, TipRanks, recent market data.